N
Google TrendMATTHEW STONE SR (200+) — Adult victims, suspected shooter ID'd in Erie mass shooting
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:matthew stone sr200+selma blair2000+al-nassr vs neftchi fergana5000+samantha busch500+crimson rescued mountain lion cub500+peggy flanagan200+sean combs10000+boeing 747500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "High-Risk Smoldering Mult" (30 stories)

Top Headline Story

Exploring the Shifting Treatment Paradigm for Smoldering Multiple Myeloma
Lead StoryHematology Advisorgeneral
Sep 25

Exploring the Shifting Treatment Paradigm for Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOR3VTUUlJaHRRSnlEeHJhdFdvOC1YdHl5OUNRQ2R4VTR1bk1UVXBDMm4zOFdPTG1acG14S3drWmxTSWRickZZaFAtTGRsQ1gyYmxiZ3BGOUItbzQ3LTZ6QUlFQUtIbW1kVkY3TWRfb0xxYi02MVAxci11ZUFDdndvU1BWdEh2R2dmc2lzYUdnMEI3SDJK?oc=5" target="_blank">Exploring the Shifting Treatment Paradigm for Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">Hematology Advisor</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+23m ago

matthew stone sr

Adult victims, suspected shooter ID'd in Erie mass shooting

Filter stories
2000+43m ago

selma blair

Selma Blair arrested for biting flight attendant, trying to open plane door

Filter stories
5000+53m ago

al-nassr vs neftchi fergana

Al Nassr Asian Champions League clash in doubt over Riyadh security situation

Filter stories
500+53m ago

samantha busch

Kyle Busch’s Widow Samantha Calls His Death ‘Unfair’ After ‘Emotional’ Celebration for Beloved NASCAR Star

Filter stories

Search Results for "High-Risk Smoldering Mult"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial
Naturegeneral

Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBNZk1nWEpWUGlOTnNjbVN4T0V0VjdLZmJaVF9nRm1fUzlZbEplM2dVOU5mVU13SEZkYXFOUTB4SWRNTlFuN2M4VEs1WndRVDVHa19fOW9URUxRekNrWkhZ?oc=5" target="_blank">Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma
CancerNetworkgeneral

Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQT1k3clBaUUFFbloySHd3UkZWcGtNS3NMaHpyY1dkU2swc1VnNEV3VEhVTkY4MXFWcjEzbnBxNFRmTnhpNVV4aTk1cWhjZjh5R2ZrQmUyY2Q2YWxheElMRUF1eXFuRmY5M2hZd1VzQUdqQS1qOFhlYjVrdkRoR1BkOFVCNTlDdTAyYkJjY1IyS3p4Z1RuaFBBR2tuX3RJNVloc1JtWDZFd3M5dFF4cHU0?oc=5" target="_blank">Linvoseltamab Shows Deep Responses in High-Risk Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
The ASCO Postgeneral

High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYlF3R25lcV9JanBzS1JibHBKaUdRNnVDX0RpOHFPc1dBR19RRXVva0tXUHlSdTNZVjRuM2FjQ0tENnlScnNXVmtfRjVhTXFZYVllcWR0UnlEcmpkX2libG8zZncyRF9vRURDMFpzS3ZrZ2pSODdmNFNtWlIwbHFVZFJnM1kxYm90VmtiN2ZCV25oUC12MEJaUzhxbVFQcjZudEJsaE1Kc1NfZkxIWTVXTmY4MTF0ODNLdVJ0ckdDaXo?oc=5" target="_blank">High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Why Surveillance Remains a Valid Choice for High-Risk Smoldering Multiple Myeloma
ASCO Daily Newstech

Why Surveillance Remains a Valid Choice for High-Risk Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQRFVkZmJQYVJEcmxqMlJLY2x4alpEN3NhbFVyWGk2Wld2RXpNbGNHSnI2VEhWT1F0aTdjcGY4TEJ4elVaeEpaVXprRnlxUl9HdmtHbUZsUzVFaHBWVHFvT2ktLW1obndSNHMyZWlBRExSdW84UHR6SVpWVzFaaWFCRk9XRVRPTnNNRGxFTXhqMEF6cDdTNlF1cTNZZkotMFVtRnc?oc=5" target="_blank">Why Surveillance Remains a Valid Choice for High-Risk Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Teclistamab Shows Promise in High-Risk Smoldering Multiple Myeloma
Oncology News Centralgeneral

Teclistamab Shows Promise in High-Risk Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxONHhHSWhUbjdmelUzM2xhbWJMQW1oUXVsZmpNalItWUdvdUpSUXlja3Vuc3dDVnAzNDVmM2dwZlRTQXdMR04yLVM0eWxHN0k2ZF8tX2N6SE5Xc2dNWk1GUmszaEdrRTZCNlBiQUNsYWZ6NEJmVEJtMkRtMGNyQ3p5VUQ2Q0dIYUlUNUdkZlZNeGdoLXhzVVNUTmhfUmJuMWx0czZEVk5MQ3NVb2F5QzU4?oc=5" target="_blank">Teclistamab Shows Promise in High-Risk Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma
OncLivegeneral

Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQZDdWQ3JKZDlsSjhrNFpDY1B0eU02cV81N19ncmViUGpKOWliNE5fWk5pbERIeEN4QWQwNFpxMkRtdDdPaDFqRXdXNnNyV0NtbHdXSnR6YnQyTllubnZPU3ktcXVhOXZsTkNLTURYWl9jM1JGZXNlamtOS0lJS25FU1l0Z3JzMUN0SERXbDlGUjRDZTRfNGwyNERsQzhGX2RldTBvUDJmUGxOOUhvVmc?oc=5" target="_blank">Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
EHA 2026: Early intervention with teclistamab achieves deep remissions for high-risk smoldering multiple myeloma
Oncology Centralgeneral

EHA 2026: Early intervention with teclistamab achieves deep remissions for high-risk smoldering multiple myeloma

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNMEJId0VLeVNjZ1JPODBEQlQweC1ZY0R3UDFLS0JRLTZwQ3dKVm1JZkU4WW9DZ0N6Tmp1aUV2VDZIVkRGQmYtb1RCYURKbjltRmZCR3JvaFc4RVFEV2dST1l4NWpSM05nZ2JBa24zSkdvbmRvTHJwdHcxeFcxdWIyTFY5aW9JNmkySXFvXzhnZUEwY3VSTWxQWTVwX1RRSTJuX2oyVDNTcWg1azBjUkRNdUQ5VmEzczR0cVhXaDU0cWZ5VWo0V0Z5aElOSmN0SjgzS0lwcE5KVnNuV1dB?oc=5" target="_blank">EHA 2026: Early intervention with teclistamab achieves deep remissions for high-risk smoldering multiple myeloma</a>  <font color="#6f6f6f">Oncology Central</font>

Read Full StoryMore like this
Smoldering Myeloma: The Treatment Issue Is Getting Trickier
Medscapegeneral

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPUG5vNDBwU2JfNjJJUzFRN29qTFFoejRwTFZkVTlLOHh5SVZ6bS1HYUtlNGZrZ1BGZ1FYMnNCWWNhU3p4blQzemNDUndRT3VxVE5WVzZabzc2Rmd5UHZTMS1makdWci15SXVkZ1c5ZjlKR1RtMEZCdG0yaVo5cnpmRV9rbHpHZWhpb0ExaVFOQXNCeWl0TVFlWlNudEE4ZDhzRVpB?oc=5" target="_blank">Smoldering Myeloma: The Treatment Issue Is Getting Trickier</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Naturegeneral

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HUjF1MXo4U0lPckpRNWZjclpIMjRmb29kd2xkbXhtOGYteV9SSEI3OTlkcm9WVjJrcUFFaG1oZGRNeTlmNVVWR1dlRWpUc1RzNzV2RTdOamY5czRIVW04?oc=5" target="_blank">Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Quadruplet Combo Appears Effective in High-Risk Smoldering Multiple Myeloma
CancerNetworkgeneral

Quadruplet Combo Appears Effective in High-Risk Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPZnIydWJ2QzlmeVlCX1JfNGJieXBiMm5CenhKcGRlQXZGS054WDZLMnNmZnNyeE9wOEJmMlM0SkJkZnBaYlhmdEFzMUU5Y2JQSXdvdXpGWGtMWjh6ZmQ4WXF1cDRpUXJVNkVvNVQ5RXN6d0thaGlBX3hJTXA0eHlydl9lLWZHaHQ1NUMzLWtXanlaOVJ5SzZ0SnZZdWYyOVNLV242UGk2UmtuNzdvRF9z?oc=5" target="_blank">Quadruplet Combo Appears Effective in High-Risk Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
When Should Oncologists Treat Smoldering Multiple Myeloma?
ASCO Daily Newsgeneral

When Should Oncologists Treat Smoldering Multiple Myeloma?

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNSGpxTWtseEZlN3ZKOTBSNER6LU1MLUNmR1NrcE93bEJsbVBnRHdQZ2ZDQS0yYXgwQlI2SWJuM2lwaWhmVEhiQWN0bUJCVHpBd0NUQlpJdmJoWGtKZXRUcXFQNjQzY0FTVHVRQ0FnSXNXLU00X1laR05LODdsb2JJRFNib3FkZmpQNWlYeGEtdw?oc=5" target="_blank">When Should Oncologists Treat Smoldering Multiple Myeloma?</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Smoldering multiple myeloma in transition: redefining early myeloma in the modern era
Naturegeneral

Smoldering multiple myeloma in transition: redefining early myeloma in the modern era

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBFWEhuVFc2RHBxWmlfMEkwdGVxdUJlX0RJOU9GQjBEQjJRZFc5dEJyNDZna3Z2ZWtHSlFkTndXa3JNX3JBLWkzR2ROdWtCSHg5NWVadU5wbkpMS2d2azJJ?oc=5" target="_blank">Smoldering multiple myeloma in transition: redefining early myeloma in the modern era</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
How Has SC Daratumumab Affected Smoldering Multiple Myeloma Treatment?
CancerNetworkgeneral

How Has SC Daratumumab Affected Smoldering Multiple Myeloma Treatment?

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbm5abFk5Q09ZN1htbUthYTBIZUFJbGFwZ1c0cW5uRXhXUmd2c0tENm1kQk5ESS1BcjdIZjEzVEpVUVhIWENocVg4ODBVMkd4N01kUzVKVjlNVXFfUm1rQy1MQXZPSFRfUnpremM0alZsQ1hOeU52ampsVlFGWWNYaEhYX0tFbzBza2dZam9sUjcwSUlVaVY5aWZFVUtGTDRpcmhpcWtiWmw?oc=5" target="_blank">How Has SC Daratumumab Affected Smoldering Multiple Myeloma Treatment?</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial
CancerNetworkgeneral

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOX0EzdXJMY0pITHNCS28xTHhkM1hVblJnS3dIMFJoakNIVmJucGlPQ1g5MVplUnJaWDNfZDRfdC1VbXdlazZKS05MZDdnODFWemVIOEVzeVZxeDl1bFlLcWduQkZxUHZzX053b3dkRnktWVNiRm1ySXdXUDRqVHZSbDM5SzYybHhETGxRYmlKOE4wa0NEQlBxQkxYTUxEQkl6ZWZvNWdKdHFWYUhwM3E4R0ZLd3hRVm1FUHh4YkhvMTRfYTljN3RZbA?oc=5" target="_blank">Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Redefining light-chain smoldering multiple myeloma: prevalence and progression risk
Naturetech

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB6M05yNGVnUlRrSWY0SE1fZlVlNGlwQzFEemNoVDE0WkN3bU1NMEJEb0JhckhNU28zYUlscVdpYUNobE50OVJLY3dFb2VJemR0czdYRGRJM3BnLTQ5X2tB?oc=5" target="_blank">Redefining light-chain smoldering multiple myeloma: prevalence and progression risk</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
Naturegeneral

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5BRkJSd09lWl91alZYMDJUeE9vUmtVQl9tZmxzdnB5Y25NVWJTdTBNaXdSYV96OGFTbFNFZ3R1Y0NROTQ2T2JGSHVONTAwd25WVUZOTkFGUnE0bm9Tdy1N?oc=5" target="_blank">Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Elranatamab Shows Strong Efficacy Signal in Smoldering Multiple Myeloma
CancerNetworkgeneral

Elranatamab Shows Strong Efficacy Signal in Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNNnlBQVlJR21aaGxwb2czS0lSaWZENGFpVWV5VEs0YjZuSG5aS0pjNHFVRThwNUVJT2tQQTVlNEVGSDA5cHhFYVd5THYyaXZuV0V1aGN4Rk0zbEt3MGhaTlVyckxQbzJMYzQtRmhCQnRUS2lGakRONk5NZ2dqYzhpSTNkS1Rfd0tCRWtYVmtVTk82VXhZMy1RSUtyeXNudTM3XzM1S1NUcmo2UQ?oc=5" target="_blank">Elranatamab Shows Strong Efficacy Signal in Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients
Natureworld

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9HaDRmUVVtR2lORVJudDZaUTladlBtZUxzSWdtV1VGZS1vWHRlb3lDOWhKLUtZSkwxOVp3TkhvVVV2NTZJYWlndGhZTWVKNWZoM3ptMk53Zm1BYWVCN3FF?oc=5" target="_blank">A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Enhanced dynamic risk stratification of smoldering multiple myeloma
Naturegeneral

Enhanced dynamic risk stratification of smoldering multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1CZGNvSnhTXzNLMHU0T3U0eE1vQjl0VUticTZqYWpHWlRRYXJxY1JiVEp6Q1hVeXJQSnNEdWs3UnJLel9NSllyTnZXOXZHZUlqd3NXUlJVUEJSelRibUNj?oc=5" target="_blank">Enhanced dynamic risk stratification of smoldering multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
AACR 2026: 100% MRD-negativity rate achieved for high-risk smoldering multiple myeloma
Oncology Centralgeneral

AACR 2026: 100% MRD-negativity rate achieved for high-risk smoldering multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQME40Mlh4ZXllNmNMOERvbkp6N3FJeGROOTMtUkwzZEpfM2Rna0JxNDNIN2gxUW9Gb3hEMWdLMEpTbjdFNEd4UEZJZWMteGdzSjctX2c2M2xoR1FqZWNEaHhQcUN0M0cta1NXTV9aTG9FQV9DOVItZTRWOHpBUEtkeFNoYW9KVVpadlhDNUVzVTdsRldUc0toa2xkN2daX3pTdGF1S0F3c29vTXlFZjFqSEM3eEpsemtIM3c?oc=5" target="_blank">AACR 2026: 100% MRD-negativity rate achieved for high-risk smoldering multiple myeloma</a>  <font color="#6f6f6f">Oncology Central</font>

Read Full StoryMore like this
Evaluating Early Survival Signals and Treatment Timing in High-Risk Smoldering Multiple Myeloma
CancerNetworkgeneral

Evaluating Early Survival Signals and Treatment Timing in High-Risk Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQS0dPTGtVS0FfWjM3bE1Vd0RMSFRoMGFXUTRaMEM0b2s4b0lnT1Nua191amhFUWZNY3R4Y1BUNk9BNHdVQnlHMUJaLWdqbVJnWDFhY1ZXWFRDYnMtWmpvYlNLZmJZT0lGN011TjlLWDRlWm5ONjBpSjBBR0tQbUVBLVZzOUh3QjFIdjZneDlId0FNcktoWC1jTW15eVBuMTU5SHpLQ3UwWnk0UG4wWHF5VkxGZ2NmNkxDWUh2V09vYy00dmM5amZlSUtB?oc=5" target="_blank">Evaluating Early Survival Signals and Treatment Timing in High-Risk Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Better Risk Stratification May Refine Early Myeloma Treatment
The American Journal of Managed Caregeneral

Better Risk Stratification May Refine Early Myeloma Treatment

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNaGVOLVBzRUgtQXZGZ1VyZ1haWlpoc3BKVUM0SEN2bzVwandSNGE2aTd6dWFHSmZNWlkyR0RDTFE2N2YyTXBlUk05amtzSWlFa0N6M2FMZTQ1SWlHZUZnN2cycGJrNUFvXzNyMGowTWRRNGozcDc5T0s2TXNsY21aODV6cHdvZmRUMFh3YzBkRmI?oc=5" target="_blank">Better Risk Stratification May Refine Early Myeloma Treatment</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
What You Should Know About Smoldering Multiple Myeloma
Health.comgeneral

What You Should Know About Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE55a09WLWVFMGR6TG1NNGFmMDBqUnZ5cS0wUllTOEVldklERjN6a2g4SUlHRW1vYXY4XzMxMUI4T0FfWmhMR3lfdjBfS3Z0ejRpaFdZektBMGdhWVBPcUlRZTZiM0ZyNmV1RXc?oc=5" target="_blank">What You Should Know About Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">Health.com</font>

Read Full StoryMore like this
Bloodlines Series: What Is Smoldering Myeloma?
American Association for Cancer Research (AACR)general

Bloodlines Series: What Is Smoldering Myeloma?

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPTjBVREt3Sm13c29Xd1hmZE45Wk10TjZCZDN5T0xFbTRXa3l2V2Z1dmJhbzh5VlVUaFBJcXVRNjRFNm1sODN2WXVrWDVGeXJhN1JVa0RxR3JNYUFVUnVJWFBSdE90bnVrbk85b1NySzRZbTBTM1hlUV8tVXhkbGZCTFJ3Q25uOTNjMHc?oc=5" target="_blank">Bloodlines Series: What Is Smoldering Myeloma?</a>  <font color="#6f6f6f">American Association for Cancer Research (AACR)</font>

Read Full StoryMore like this
Exploring a New Era of Treatment for Smoldering Myeloma
Targeted Oncologygeneral

Exploring a New Era of Treatment for Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQd3lEUUNlZGJtV3VKczEzV1JzM1ZjZEVTRmJKV3I5Y01QZDhaWjVydVd5UUdOSC1jb3FpN3VFRTYyR3ZOb0pSWEpwMm10dnJlMTZNOTU0N2NsVzctRVdnbzR3d2ZJU01xMnZEbzhVbzRad2RBaEFKMjlveGVWZ3pmMVdQQ2hwZURBcTZCSHJ4MUtudw?oc=5" target="_blank">Exploring a New Era of Treatment for Smoldering Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD
The American Journal of Managed Caregeneral

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPWFFYOWt1X3ZEeFdaZTRwNjc4YmQ3Q0dNdmpOdTh1SUdwTHRnYVlMMWNrYzNsT2JfZUhfNEpaY2FzNVRwOHh4RG1XRXhjbUtGaGF3b3Z2ZkNLMEV3UmVwWm00TjlsMnpWZXBxVE9iVGwxR1BOWjU5bjROUzF1WFNBYWtZUWg3angzYXJpUVBxT1kweHQ1bEJuNDVWeXRqWUdEc0NMWExKU19Bcy1Ec19mZjZkYzdNUW15OUdfWXVfVzJWWklrWWFn?oc=5" target="_blank">Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma
Targeted Oncologygeneral

Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQck5rOTg2eEVfWmZ0UnFIcVJCT0tOMXBrWUdnMjJmSEdaRUdtTnR2ay1FRUczb20tWDNJcmRlZkxETjVuVFNVY01ZOEZqZDdUVGgyckEtMHVIcl9YUXh1Ry10algyXy1mTWs2X3NRSnppOEV5dzJkLTREOWRUcTUwSlE5OUNTR1F5YkhrRUZRcEp4R255UU1LT3hiNVZWLVNkVlE?oc=5" target="_blank">Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Which Risk Model Better Identifies High-Risk Smoldering Multiple Myeloma?
Medscapegeneral

Which Risk Model Better Identifies High-Risk Smoldering Multiple Myeloma?

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOLVA0XzRaZTZYN0dvdE11ekJDc2FJV185Z2FDeml1M2NPaFMwd3FiRUNVNWJyY0VKOWQ5OVdGeVFkS0I4YVdFUGJyQ0FzdGVQS1FIbTZMb2FJSk5EYmJQV1BCaGZvYzhxdVU0R2tHazNjOVE1WWdwODhYTVJyTHI3aXR5YnFLVDRrS3ZnRmRic1FZb0prbXVwQU1RdGtGb1BzLW9WTjFqUWY?oc=5" target="_blank">Which Risk Model Better Identifies High-Risk Smoldering Multiple Myeloma?</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
CancerNetworkgeneral

New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxObXR4MDNKU3EydEJSeldwbHNFS2I0M3IwUHREZHUzZHJCU2d2Z0VpX0MtMzh2V25MZGR1N1JaUGxUU0ZGaDNhd0g4c1F5d2xlS0hNZ2ZTbTRVRFFPQnhvSHUyQVExeEphNUdMSm5nX1VRSnNXTlZONnNyVzRBREx5bVhUQUtnMHRMT0VwTVduOVJNU1pSUE8yQlBhWERTY09QUnZHUjhfUDJGLVhP?oc=5" target="_blank">New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"High-Risk Smoldering Mult" — Live Google News Trends & Headlines